Table 2.
Association between use of Acetylcholinesterase Inhibitors and all-cause mortality.
| AChEIs use | Post-surgical outcomes | Crude HR (95% CI) | Adjusted HRa (95% CI) | |
|---|---|---|---|---|
| Second hip fracture | ||||
| No (n=414) | Yes (n=118) | |||
| Non-user | 237 (57.3) | 72 (61.0) | 1 | 1 |
| User | 177 (42.7) | 46 (39.0) | 0.74 (0.51,1.08) | 0.59 (0.38-0.94) |
| Ipsilateral hip reintervention | ||||
| No (n=503) | Yes (n=29) | |||
| Non-user | 293 (58.3) | 16 (55.2) | 1 | 1 |
| User | 210 (41.7) | 13 (44.8) | 0.94 (0.47-1.96) | 0.72 (0.27-1.92) |
| All-cause mortality | ||||
| Alive (n=350) | Dead (n=182) | |||
| Non-user | 199 (56.9) | 110 (60.0) | 1 | 1 |
| User | 151 (43.1) | 72 (40.0) | 0.65 (0.48,0.88) | 0.44 (0.30-0.63) |
a
Adjusted for: age, diabetes, ischemic heart disease, renal disease, duration of Alzheimer’s disease (<2, 2-6, >6 years) and use of selective serotonin reuptake inhibitors, hypnotics, proton pump inhibitors, diuretics, statins, history of falls and pre-baseline use of acetylcholinesterase Inhibitors. Abbreviations: AChEIs - acetylcholinesterase inhibitors, HR - hazard ratio, Ci - confidence interval.